consolidation therapy for unresectable stage iii egfr-mutant nsclc
Published 10 months ago • 68 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
2:39
assessing the role of consolidation therapy for egfr-mutant nsclc
-
5:59
targeted therapy in consolidation setting for lung cancer
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
6:00
osimertinib improves pfs in egfr-mutant, unresectable, stage iii nsclc
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
1:44
post-hoc subgroup analysis from pacific: durvalumab after crt in unresectable stage iii egfrm nsclc
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
0:55
osimertinib for egfr-mutant lung cancer
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
4:01
gemstone-301: sugemalimab versus placebo for phase iii nsclc
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
14:24
egfr-mutant lung cancer & treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
4:58
tops mount sinai: consolidation treatment post-ccrt in unresectable stage iii nsclc
-
20:35
tki-resistant egfr-mutant nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
7:38
unresectable stage iii lung cancer management
-
1:01
impact of durvalumab as consolidation therapy in nsclc